Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

By sjmartinez • April 9, 2024

Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00568-1. doi: 10.1016/j.jaad.2024.03.041. Epub ahead of print. PMID: 38588819.

Tags: alanine aminotransferase, aspartate aminotransferase, bimekizumab, Dermatology, enzyme, Hepatic, Liver, liver fibrosis, plaque psoriasis, psoriasis, Publications, safety, transaminase

A scalp to make you squirm: Cutaneous myiasis hiding a unique presentation of disseminated coccidioidomycosis

Duldulao JM, Modanlo N, Boppana S, Adachi K, Dong HV, Kaur I, Nielsen-Saines K, Terrell J, Cheng CE, Malhotra S. A scalp to make you[...]

Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals

Matthews R, Armstrong AW, Augustin M, Baker C, Carrascosa JM, Kirby B, Langley R, McBride S, Reich A, Romiti R, Sampogna F, Warren RB. Is[...]

T cell-macrophage interactions in tuberculosis: What we’ve got here is failure to communicate

Mortensen R, Arlehamn CSL, Coler RN, Gerner MY, Goletti D, Lewinsohn DA, Modlin RL, Musvosvi M, Rengarajan J, Urdahl KB, Walzl G, Behar SM, Barber[...]